Download Free Medical Management of ARDS and refractory hypoxemia in covid19 patient PowerPoint Presentation

Management of ARDS and refractory hypoxemia in covid19 patient PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical titled "Management of ARDS and refractory hypoxemia in covid19".

This medical talks about Management of ARDS and refractory hypoxemia in covid19.

Acute respiratory distress syndrome (ARDS) and refractory hypoxemia are severe respiratory complications that can occur in COVID-19 patients. The management of these conditions typically involves a multi-disciplinary approach and may vary depending on the severity of the illness and the underlying causes of the respiratory failure.

Tags : covid19, Acute respiratory distress syndrome, ARDS, refractory hypoxemia, Emergency Medicine, Emergency Medicine

Published on : Apr 14, 2023 | Views : 770 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Management of ARDS and refractory hypoxemia in covid19 patient
Slide 2-

ppt slide no 2 content not found
Slide 3-

Management of ARDS
Slide 4-

Lung protective ventilation in ARDS
Slide 5-

Lung protective ventilation in ARDS
Slide 6-

ppt slide no 6 content not found
Slide 7-

ppt slide no 7 content not found
Slide 8-

Refractory hypoxemia
Slide 9-

Refractory hypoxemia
Slide 10-

Modalities for refractory hypoxemia
Slide 11-

NMB
Slide 12-

Recruitment maneuvers
Slide 13-

Recruitment maneuvers
Slide 14-

Prone positioning
Slide 15-

ppt slide no 15 content not found
Slide 16-

ppt slide no 16 content not found
Slide 17-

Prone positioning
Slide 18-

Prone positioning
Slide 19-

iNO Inhaled pulmonary vasodilators cause selective pulmonary vasodilatation in well-ventilated lung units resulting in better ventilation-perfusion matching and improved oxygenation in ARDS patients Inhaled vasodilators have short half-lives and therefore are associated with lesser systemic side effects such as hypotension. iNO is costly, gets rapidly inactivated by hemoglobin, requires specialized equipment, and can result in methemoglobinemia (usually above 40 ppm, dose range - 2–80 ppm).
Slide 20-

ppt slide no 20 content not found
Slide 21-

HFOV
Slide 22-

ECMO
Slide 23-

ECMO
Slide 24-

Complications
Slide 25-

Adjunt therapy
Slide 26-

ppt slide no 26 content not found
Slide 27-

ppt slide no 27 content not found
Slide 28-

ppt slide no 28 content not found